-
Sarepta Therapeutics Initiates Dosing in Phase I Multiple Ascending Dose Study of Drug for Treatment of Marburg Virus
Sarepta Therapeutics, Inc. , a developer of innovative RNA-based therapeutics, today announced that it has initiated dosing in a Phase 1 multiple ascending dose clinical trial of AVI-7288, the Company's ...
Marketwired via Yahoo! Finance -
Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical ...
BLUE BELL, Pa., May 14, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of Inovio's SynCon ® DNA vaccine against Ebola and Marburg filoviruses, ...
PR Newswire via Yahoo! Finance -
Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments
Sarepta Therapeutics, Inc. , a developer of innovative RNA-based therapeutics, today reported financial results for the three months ended March 31, 2013, and provided an update of recent corporate developments....
Marketwired via Yahoo! Finance -
Anthrax, Ricin, Smallpox: Which Is the Deadliest Bioterrorism Agent?
In between the Boston Marathon bombings and the devastating explosion in West, Texas, last week, Americans also heard about the interception of several pieces of mail meant for President Obama, Senator Roger Wicker, and a Mississippi judge. All contained ricin, a poison made from castor beans. After 30 years of relative obscurity, ricin was back in the news as a bioterrorism agent.
Takepart.com via Yahoo! News -
BIOL Does A Deal, BLRX's Lined Up Events, CBST On Fast Track, KERX On Watch
BIOL Does A Deal, BLRX's Lined Up Events, CBST On Fast Track, KERX On Watch
Nasdaq